C11orf70 Inhibitors
C11orf70 inhibitors are compounds that act on specific signaling pathways and biological processes to indirectly decrease the functional activity of this protein. LY294002 and Wortmannin, for example, inhibit PI3K, which is a crucial upstream regulator of the AKT pathway. Since AKT is involved in a wide array of cellular processes, such as growth and survival, the inhibition of PI3K by these compounds may lead to reduced AKT activity. If C11orf70's functional state is maintained or modulated via the PI3K/AKT pathway, the action of these inhibitors would result in the diminution of C11orf70's activity. Similarly, Rapamycin, which targets mTOR, could disrupt protein synthesis and cell growth processes. If C11orf70's activity is associated with mTOR's role in cell growth, Rapamycin's inhibitory effect would extend to diminishing C11orf70 activity.
Additional compounds like U0126 and PD98059 exert their effects by inhibiting the MEK/ERK pathway. This pathway is critical in various aspects of cell signaling, including cell cycle progression, differentiation, and apoptosis. The MEK/ERK pathway is a common conduit for many growth factors and mitogens. Therefore, when U0126 and PD98059 inhibit MEK1/2, they effectively block the activation of ERK1/2, potentially leading to reduced activity of proteins that are regulated by this pathway. If C11orf70 is one such protein, then its activity could be reduced as a consequence of MEK inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
An inhibitor of PI3K, LY294002 binds to the ATP-binding site of PI3K, preventing its activity. This leads to a reduction in the downstream signaling of AKT, which could indirectly inhibit C11orf70 if AKT signaling is required for C11orf70's activation or stabilization. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that irreversibly binds to the PI3K enzyme, blocking the PI3K/AKT pathway and potentially decreasing activities that rely on this signaling, including those that may activate C11orf70 functionally. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR by binding to its intracellular receptor, FKBP12, forming a complex that inhibits mTORC1. This inhibition can suppress cell growth and proliferation processes, possibly affecting C11orf70 activity if it is involved in these mTOR-regulated pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which impedes the activation of ERK1/2, a part of the MAPK/ERK pathway. By inhibiting this pathway, U0126 may indirectly decrease the activity of C11orf70 if it is regulated by ERK signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which indirectly prevents the activation of ERK. If C11orf70 activity is contingent on ERK signaling, this inhibition could lead to reduced functional activity of C11orf70. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
As an inhibitor of p38 MAPK, SB203580 suppresses the kinase's ability to phosphorylate its substrates. This action could lead to a decrease in C11orf70 activity if p38 MAPK signaling influences C11orf70's function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that may diminish the phosphorylation of c-Jun and other transcription factors within the AP-1 group, potentially affecting the functional activity of C11orf70 if JNK signaling modulates its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A Src family kinase inhibitor, Dasatinib could reduce kinase activity that may be upstream of pathways affecting C11orf70's activity, leading to its functional inhibition if Src signaling is involved in C11orf70 regulation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases including RAF kinase, VEGFR, and PDGFR. If C11orf70 is regulated by any of these kinases' signaling pathways, its activity could be reduced by Sorafenib's action. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib inhibits CDK4/6, halting cell cycle progression at G1. This inhibition could affect the functional activity of C11orf70 if its activity is linked to cell cycle phases regulated by these kinases. | ||||||